Glioblastoma News and Research

RSS

Glioblastoma is the most aggressive and malignant form of glioma, a type of primary brain cancer. Surgery is often used to treat gliomas, along with radiation. However, since surgery and radiation fail to cure the disease, doctors may turn to additional radiation or chemotherapy. In early stages glioblastoma tumors often grow without symptoms and therefore can become quite large before symptoms arise. When the tumor becomes symptomatic, tumor growth is usually very rapid and is accompanied by altered brain function, and if left untreated the disease becomes lethal. Although primary treatment is often successful in temporarily stopping the progression of the tumor, glioblastomas almost always recur and become lethal.

Electrical currents could supercharge cancer-killing immune cells, study finds

Scientists have discovered that electrical currents may make Natural Killer (NK) cells – our very own cancer-killing immune cells – even better killers, which could have significant implications for treating some cancers.

25 Jul 2024

MD Anderson and Summit Therapeutics partner to accelerate ivonescimab development

The University of Texas MD Anderson Cancer Center and Summit Therapeutics, Inc. today announced a strategic five-year collaboration agreement for the purpose of accelerating the development of ivonescimab.

25 Jul 2024

New technique could one day be used to target glioblastoma

Tackling brain cancer is complicated, but groundbreaking new research could help add another tool to the cancer-fighting arsenal.

17 Jul 2024

Study highlights the role of RGS16 in glioma progression

Gang Li et al., at Department of Neurosurgery, Qilu Hospital, Shandong University, China, presented a comprehensive study on the role of regulator of G-protein signaling 16 (RGS16) in the progression of glioma, a highly aggressive central nervous system tumor.

17 Jul 2024

Targeted alpha therapy offers hope for glioblastoma patients

A new approach to treating the most malignant type of brain cancer – glioblastoma – has shown strong promise in pre-clinical settings, raising hopes of increasing current average survival rates beyond 18 months.

10 Jul 2024

FDA expands orphan drug designation for Roswell Park's brain cancer immunotherapy

The U.S. Food and Drug Administration (FDA) has expanded orphan drug designation for SurVaxM, a brain cancer immunotherapy born in the labs of Roswell Park Comprehensive Cancer Center.

25 Jun 2024

Iontronic technology shows promise in slowing malignant brain tumor growth

When low doses of cancer drugs are administered continuously near malignant brain tumors using so-called iontronic technology, cancer cell growth drastically decreases.

19 Jun 2024

Rapid test detects brain cancer mutations in cerebrospinal fluid

A test that looks for genetic hallmarks of brain cancers in samples of cerebrospinal fluid can decrease the time to diagnosis and eliminate the need for invasive brain biopsies for some patients.

17 Jun 2024

Study sheds light on pediatric DIPG tumor mechanisms

Researchers at the University of Michigan Health Rogel Cancer Center are one step closer to understanding how pediatric DIPG tumors work.

13 Jun 2024

Combining anlotinib with STUPP regimen improves survival in glioblastoma patients

Glioblastoma multiforme (GBM) is among the most aggressive forms of brain tumors, with few effective treatment options and a bleak prognosis.

12 Jun 2024

Johns Hopkins researchers discover how epilepsy drug modulates brain activity

By super cooling a molecule on the surface of brain cells down to about minus 180 degrees Celsius -; nearly twice as cold as the coldest places in Antarctica -; scientists at Johns Hopkins Medicine say they have determined how a widely-used epilepsy drug works to dampen the excitability of brain cells and help to control, although not cure, seizures.

10 Jun 2024

Ultrasound technology breaks blood-brain barrier for glioblastoma treatment

In a major advance for the treatment of the deadly brain cancer glioblastoma, Northwestern Medicine scientists used ultrasound technology to penetrate the blood-brain barrier and provide a small dose of a chemotherapy and immunotherapy drug cocktail.

6 Jun 2024

Study identifies PI3K-beta as key target in overcoming chemotherapy resistance in glioblastoma

For many patients with a deadly type of brain cancer called glioblastoma, chemotherapy resistance is a big problem.

20 May 2024

Combination immunotherapy treatment enhances immune response for people with malignant gliomas

Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have pinpointed a combination immunotherapy treatment that enhances the immune response for people with malignant gliomas, an aggressive type of brain tumor that is fast growing and difficult to treat.

9 May 2024

Researchers enhance CAR-T cells to target solid tumors

Researchers at the National Cancer Institute-designated Montefiore Einstein Comprehensive Cancer Center (MECCC) have shown that a breakthrough therapy for treating blood cancers can be adapted to treat solid tumors-;an advance that could transform cancer treatment.

8 May 2024

Innovative nanoparticle breaks blood-brain barrier to target breast cancer and brain metastases

Researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have developed a nanoparticle that can penetrate the blood-brain barrier.

6 May 2024

Unlocking glioblastoma's immune suppression mechanism

The Wistar Institute assistant professor Filippo Veglia, Ph.D., and team, have discovered a key mechanism of how glioblastoma -; a serious and often fatal brain cancer -; suppresses the immune system so that the tumor can grow unimpeded by the body's defenses.

3 May 2024